Jim Mullen, Editas Medicine chairman

Ex­clu­sive: Strug­gling Ed­i­tas shops pre­clin­i­cal can­cer pipeline dur­ing its big makeover

Sto­ried CRISPR gene edit­ing pi­o­neer Ed­i­tas Med­i­cine $ED­IT is in ad­vanced dis­cus­sions re­gard­ing the sale of the pre­clin­i­cal on­col­o­gy line­up in its pipeline as the biotech works through a makeover of the com­pa­ny, its ex­ec­u­tive team and the drugs it hopes to take through the clin­ic, End­points News has learned.

Can­cer drugs sit on the bot­tom rung of the totem pole in Ed­i­tas’ R&D group, but in­cludes the iNK treat­ment ED­IT-202, which was re­cent­ly tout­ed by the biotech as a ther­a­py that fea­tured “dou­ble knock-in and dou­ble knock-out ed­its.” The pre­clin­i­cal pro­file of the nat­ur­al killer can­di­date of­fered a shot at prov­ing greater dura­bil­i­ty and per­sis­tence for an al­lo­gene­ic — or off-the-shelf ap­proach — against sol­id tu­mors, one of the holy grails in drug R&D these days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.